Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 1
2004 1
2007 2
2008 3
2009 3
2010 4
2011 7
2012 6
2013 6
2014 6
2015 8
2016 11
2017 6
2018 13
2019 8
2020 6
2021 7
2022 5
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

101 results

Results by year

Filters applied: . Clear all
Page 1
Corrigendum to "Non-covalent strategies to functionalize polymeric nanoparticles with NGR peptides for targeting breast cancer" [Int. J. Pharm. 633 (2023) 122618].
Conte C, Longobardi G, Barbieri A, Palma G, Luciano A, Dal Poggetto G, Avitabile C, Pecoraro A, Russo A, Russo G, Laurienzo P, Romanelli A, Quaglia F. Conte C, et al. Among authors: barbieri a. Int J Pharm. 2023 Jun 25;641:123045. doi: 10.1016/j.ijpharm.2023.123045. Epub 2023 May 9. Int J Pharm. 2023. PMID: 37169105 No abstract available.
Safety profile of treatment with greenlight versus Thulium Laser for benign prostatic hyperplasia.
Campobasso D, Barbieri A, Bocchialini T, Pozzoli GL, Dinale F, Facchini F, Grande MS, Kwe JE, Larosa M, Guarino G, Mezzogori D, Simonetti E, Ziglioli F, Frattini A, Maestroni UV. Campobasso D, et al. Among authors: barbieri a. Arch Ital Urol Androl. 2023 Feb 22;95(1):11101. doi: 10.4081/aiua.2023.11101. Arch Ital Urol Androl. 2023. PMID: 36924373 Free article.
Corrigendum: Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathways.
Quagliariello V, Passariello M, Di Mauro A, Cipullo C, Paccone A, Barbieri A, Palma G, Luciano A, Buccolo S, Bisceglia I, Canale ML, Gallucci G, Inno A, De Lorenzo C, Maurea N. Quagliariello V, et al. Among authors: barbieri a. Front Cardiovasc Med. 2023 Jan 19;10:1129873. doi: 10.3389/fcvm.2023.1129873. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 36742077 Free PMC article.
Targeting the MITF/APAF-1 axis as salvage therapy for MAPK inhibitors in resistant melanoma.
Carotenuto P, Romano A, Barbato A, Quadrano P, Brillante S, Volpe M, Ferrante L, Tammaro R, Morleo M, De Cegli R, Iuliano A, Testa M, Andreone F, Ciliberto G, Clery E, Troncone G, Palma G, Arra C, Barbieri A, Capone M, Madonna G, Ascierto PA, Lanfrancone L, Indrieri A, Franco B. Carotenuto P, et al. Among authors: barbieri a. Cell Rep. 2022 Nov 8;41(6):111601. doi: 10.1016/j.celrep.2022.111601. Cell Rep. 2022. PMID: 36351409 Free article.
Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathways.
Quagliariello V, Passariello M, Di Mauro A, Cipullo C, Paccone A, Barbieri A, Palma G, Luciano A, Buccolo S, Bisceglia I, Canale ML, Gallucci G, Inno A, De Lorenzo C, Maurea N. Quagliariello V, et al. Among authors: barbieri a. Front Cardiovasc Med. 2022 Sep 8;9:930797. doi: 10.3389/fcvm.2022.930797. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 36158826 Free PMC article.
In PD-1+ human colon cancer cells NIVOLUMAB promotes survival and could protect tumor cells from conventional therapies.
Ieranò C, Righelli D, D'Alterio C, Napolitano M, Portella L, Rea G, Auletta F, Santagata S, Trotta AM, Guardascione G, Liotti F, Prevete N, Maiolino P, Luciano A, Barbieri A, Di Mauro A, Roma C, Esposito Abate R, Tatangelo F, Pacelli R, Normanno N, Melillo RM, Scala S. Ieranò C, et al. Among authors: barbieri a. J Immunother Cancer. 2022 Mar;10(3):e004032. doi: 10.1136/jitc-2021-004032. J Immunother Cancer. 2022. PMID: 35246475 Free PMC article.
101 results